Solutions
Advisory Services
Clinical Development
- Generics Development
- Clinical Operations
- Clinical Data Sciences
- Medical and Safety Services
- RWD & RWE Services
Post Marketing
- Safety Services
- Post marketing Studies
- Regulatory Affairs
How AI in Clinical Trials, Decentralized Clinical Trials and Real-World Evidence (RWE) Are Redefining Research Clinical research is entering 2026 with rising complexity and rising expectations. Sponsors are under pressure to accelerate development timelines, manage global operations, meet evolving regulatory requirements and deliver patient-centric...
A Year of Impact 2025 was a year of progress and partnership, where sponsors looked for the best CRO partner for global clinical trials, demanded inspection-ready clinical trial support for EMA inspections and needed teams that could deliver under pressure without compromising quality. Navitas Life Sciences worked alongside partners across clinical...
The Navitas Advantage: Powering the Future of Pharma & Biotech In today’s fast-moving world of pharma and biotech, innovation isn’t just an advantage—it’s a necessity. Scientific breakthroughs, evolving global regulations, and the relentless demand for speed and quality are rewriting the rules of drug development. To...
In a world where scientific innovation is accelerating fast, regulatory strategy is a competitive advantage. Pharma & biotech companies need clarity and deep multidisciplinary insight into the regulatory environment and the paths that competitors are taking to bring safe, effective products to market quickly. Whether developing a first-in-class...
Are you ready to lead the next wave of transformation in life sciences? Across Navitas’ industry-leading networks, pvnet®, pvconnect®, labelnet™, and more, over 100+ member companies are rewriting the playbook for 2026. Here’s what’s setting the pace for the industry’s boldest innovators: 1. Technology &...
On this World Diabetes Day, we reaffirm our global commitment to reducing the burden of diabetes. Because it embodies the science behind better diabetes care, the euglycemic clamp study stands as one of the most significant innovations in modern diabetes research. The euglycemic clamp is a symbol of precision and by offering an accurate measure of ...
Accelerating First-to-Market Success in Generics Bioavailability and Bioequivalence (BABE) studies are critical gateways to bringing safe, effective, and affordable generic medicines to market. With over 90% of US prescriptions filled by generics, ensuring robust clinical execution and data integrity has never been more important. Digital Precision...
The complexities and challenges of data is increasing at an unprecedented rate and excellence in Clinical Data Management (CDM) has become a defining factor of success. Pharmaceutical and biotech companies are looking for partners who not only manage data but transform it into meaningful insights that drive smarter and more compliant decisions. In ...
The second Navitas Life Sciences Ad Promo Roundtable, held on September 25, 2025, convened more than forty experts from across global pharma to examine recent U.S. FDA actions on Direct-to-Consumer (DTC) advertising. Highlights from the Second Ad Promo Roundtable The session was Co-Hosted by Bob Dean, Head of Global Labeling Strategy and Ad/Promo, ...
Be First-to-Market with Our Bioavailability & Bioequivalence (BABE) CRO Services Bioavailability (BA) and Bioequivalence (BE) studies are critical components in developing or marketing a generic drug. To secure approval from global health authorities such as the US FDA, pharmaceutical companies must conduct a bioequivalence study comparing thei...